Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
YB-831
- Development stage
- Preclinical
- Lead developer
- Ymmunobio
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Parenteral
01
Overview
YB-831 (also known as YB-800R2) is a preclinical-stage, radiolabeled monoclonal antibody being developed by Ymmunobio for the diagnosis and treatment of solid tumors, particularly gastrointestinal cancers. It consists of a humanized monoclonal antibody (YB-800) that targets neuronal pentraxin receptor (NPTXR), a tumor-specific marker highly expressed in various solid tumors but absent in healthy tissues. YB-831 is conjugated to a radioactive isotope, specifically terbium-161 (¹⁶±Tb), and is designed for diagnostic imaging (such as SPECT) and targeted radionuclide therapy. The development of YB-831 is supported by Innosuisse and conducted in collaboration with the Paul Scherrer Institute.
- Other names
- YB-800 R2YB800 R2YB 800 R2
02
Targets
NPTXR (Neuronal pentraxin receptor)
Beyond the preview
Go deeper on YB-831.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on YB-831.